EPHX2 and metabolic disease: Although there is experimental evidence that links sEH inhibition with improvements in inflammatory conditions, blood pressure, metabolic diseases, and even neuropathic pain [19], the impetus for the further development of such compounds was dampened by reports of a link between sEH inhibition and accelerated tumor growth [6,7,9,20] as well as increased metastases and escape from dormancy [13,21].